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Oral immunotherapy (OIT) has been reported to be effective for
food allergy in recent years,1 but most studies on OIT have focused
on a single antigen. Begin et al. ﬁrst reported the use of OIT using
peanuts and another allergen simultaneously, which was feasible
and relatively safe.2 The purpose of this study was to evaluate the
safety and efﬁcacy of multi-nut OIT initiation for a patient with
multi-nut allergy.
We enrolled a 22-year-old man who had peanut, cashew nut,
andwalnut allergies. He experienced face swelling after eating pea-
nuts at the age of one. He and his mother tried to eliminate peanuts
and other nuts completely; however, he occasionally ingested nuts
accidentally. He had conjunctival erythema, lip swelling, and a
cough after peanut ingestion at the age of 17 and generalized ﬂush-
ing, vomiting, and breathing difﬁculty after cashew nut ingestion at
the age of 21.
He was initially checked for food-speciﬁc IgE (sIgE) and
component-resolved diagnostics (CRD) using the ImmunoCAP
assay system (Thermo Fisher Scientiﬁc, Uppsala, Sweden). Food
sIgE (kU/l) was 11.6 for peanut, 3.87 for cashew nut, 6.08 for walnut,
5.92 for pistachio, 2.22 for macadamia nut, and <0.10 for almond
and hazel nuts. CRD was 0.24 for Ara h 1, 13.6 for Ara h 2, 7.34 for
Ana o 3, <0.10 for Ara h 3, 8, and 9, Jug r 1 and 3, Bet v 1 and 2,
Pru p 3, and Gly m 4, 5, and 6. Open oral food challenge of 0.5 g
of peanut or 3.0 g of each nut was conducted before OIT. Peanut
was administered at 60-min intervals as follows: 1/4 and 3/4.
Each nut was administered at 30-min intervals as follows: 1/8, 3/
8, and 4/8. He reacted to 0.5 g of peanut, 1.1 g of cashew nut, and
3.0 g of walnut. He tolerated pistachio, macadamia nut, almond,
and hazel nut.
He received OIT using peanut, cashew nut, and walnut simulta-
neously. From the day of admission, he took loratadine (10 mg)
before nut intake. On the day of admission, a double-blind, pla-
cebo-controlled food challenge (DBPCFC) was performed. The chal-
lenge food was made by mixing equal amounts of the three nuts.
From the second to fourth day in the hospital, he ingested mixed
nut powder, which contained equal amounts of the three nuts,
twice a day. During his stay, we adjusted the amount so that he
would not experience severe symptoms at home. After discharge,
he took the same amount once a day after taking loratadine. We
investigated the severity of symptoms for safety and changes in
symptom occurrence and food sIgE for efﬁcacy. This study was
approved by the Sagamihara National Hospital Ethics CommitteePeer review under responsibility of Japanese Society of Allergology.
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Written informed consent was obtained from him.
During DBPCFC, he experienced an itchy throat and moderate
abdominal pain at 1.5 g of total nut intake (0.5 g of each nut)
without any treatment. In the morning of the second hospital
day, he experienced an itchy throat, generalized erythema, persis-
tent cough, and moderate abdominal pain at 1.5 g and was treated
with an oral antihistamine and inhaled b2 agonist. After the
amount was decreased to 0.5 g of total nuts, he only experienced
an itchy throat and mild abdominal pain. He didn't need any treat-
ment except for oral antihistamine in the morning of the third hos-
pital day.
After discharge, he continued to take 0.5 g of total nuts (0.17 g of
each nut). He experienced symptoms of itchy throat, mild abdom-
inal pain, and diarrhea once at home. He took oral antihistamine as
treatment for mild abdominal pain and diarrhea only twice inweek
1. Any symptoms and each symptom decreased from the initiation
of the study to 8 months (Fig. 1).
Peanut, cashew nut, and walnut sIgE temporarily increased at 1
month, and decreased at 3 and 6 months. Ara h 1e3 and Ana o 3
sIgE changed in the same manner (Fig. 2). Ara h 8 and 9, and Jug
r 1 and 3 sIgE from pre-OIT to 6 months were <0.10 kU/l.
Less than 25%e50% of patients with peanut allergies have tree
nut allergy.3 In general, patients with peanut and other nut allergies
are not unusual. If patients withmulti-nut allergies tolerate a single
nut by OIT to a single allergen, they have to avoid the other nuts.Fig. 1. Symptom occurrence of multi-nut oral immunotherapy at home. Total dose was
202 doses. Total number of symptoms was 146 times (72.2%) for any symptoms, 133
times (65.8%) for itchy throat, 49 times (24.3%) for mild abdominal pain, and 40 times
(19.8%) for diarrhea once.
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Fig. 2. Changes in food-speciﬁc IgE and component-speciﬁc IgE during multi-nut oral
immunotherapy. Serum samples were collected before starting multi-nut oral immu-
notherapy (pre) and at 1 month (1 M), 3 months (3 M), and 6 months (6 M) after start-
ing immunotherapy. A, Peanut. B, Cashew nut. C, Walnut.
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multi-nut allergy.
All symptoms, except for the ﬁrst two moderate symptoms,
were mild, which demonstrated that he could start multi-nut OIT
safely. Our patient's symptom occurrence during 8 months was
72.2%. Begin et al. reported that symptom occurrence was a medianof 2.9% (range 0.1e59.0%).2 Other studies showed that Ara h 2 sIgE
values correlated with symptom severity by peanut ingestion.4,5
Begin's patients did not check Ara h 2 sIgE; however, our patient
had elevation of Ara h 2 sIgE and Ana o 3 sIgE. Sensitization of
Ara h 2 and Ana o 3 may affect the difference in symptom occur-
rence between our patient and Begin's patients. Furthermore, the
decreasing trend of our patient's symptom occurrence suggests
that multi-nut OIT may be effective.
Food sIgE in our patient was temporarily increased at 1 month,
and decreased at 3 and 6 months. Jones et al. reported that peanut
sIgE in patients receiving peanut OIT temporarily increases and
then decreases.6 Bird et al. reported that peanut OIT does not
decrease cashew nut and walnut sIgE.7 Changes in our patient's
food sIgE suggest that although our patient's maintenance dose
was small, each nut ingestion affected each nut sIgE. Ara h 1e3
sIgE but not Ara h 8 and 9 in our patient changed in a similar
manner to those in Vickergy's study.8
Multi-nut OIT initiation for multi-nut allergy may be safe and
may contribute to decrease of symptom occurrence and food-
speciﬁc IgE. We need to further investigate the mechanism by
which our patient was able to tolerate nuts by multi-nut OIT.
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